Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
or
LiveHelp online chat
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-6 of 6 for your search:
Drug:
bispecific antibody MDX-H210
Find trials that include:
Any drugs shown
Trial Status:
Closed
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
Phase I/II Pilot Study of Bispecific Antibody 520C9xH22 with GM-CSF for Advanced Malignancies Expressing the HER-2/neu Antigen (Summary Last Modified 12/98)
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Closed
Age:
18 and over
Sponsor:
Other
Protocol IDs:
GUMC-34594
, NCI-V96-0970
2.
Phase IA/IB Study of the Bispecific Antibody 520C9xH22 (MDX-H210) plus Interferon gamma in Metastatic Adenocarcinomas Expressing the HER2/neu Antigen
Phase:
Phase I
Type:
Treatment
Status:
Closed
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
MDX-DMS-9318
, DMS-9318, NCI-V94-0450
3.
Phase I Study of Bispecific Antibody 520C9xH22 for Advanced Malignancies Expressing the HER-2/neu Antigen
Phase:
Phase I
Type:
Treatment
Status:
Completed
Age:
over 18
Sponsor:
NCI, Pharmaceutical / Industry
Protocol IDs:
NCI-95-C-0023L
, MDX-NCI-95-C-0023L, NCI-MB-360
4.
Phase I Study of the Bispecific Antibody 520C9xH22 for Metastatic Prostate Cancer Expressing the HER2/neu Antigen (Summary Last Modified 06/96)
Phase:
Phase I
Type:
Treatment
Status:
Closed
Age:
over 18
Sponsor:
Other
Protocol IDs:
DMS-9403
, NCI-V95-0626
5.
Phase I Study of Bispecific Antibody 520C9xH22 with G-CSF for Relapsed/Refractory Metastatic Cancer that Overexpresses HER2/neu
Phase:
Phase I
Type:
Treatment
Status:
Completed
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
MDX-1B-95-2
, LAC-USC-1B952, NCI-V95-0658
6.
Phase Ia/b Study of the Bispecific Antibody 520C9x22 Given Intravenously or Intraperitoneally in Patients with Advanced Breast or Ovarian Carcinoma (Summary Last Modified 04/94)
Phase:
Phase I
Type:
Treatment
Status:
Closed
Age:
over 18
Sponsor:
Protocol IDs:
DMS-9221
, NCI-V93-0220
Select All on Page
Help with Results
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute